LAURA Trial Part 1 Podcast

Podcast | English | 2024 | 27 Min

Create Account

Cost

$0.00

Credit

No Credit Offered

Lung Cancer Considered host Dr. Narjust Florez and Dr. Suresh Ramalingam discuss the recent FDA approval of osimertinib after chemo-radiation in EGFR-positive NSCLC. The approval was based, in part, on the results of the LAURA trial, which was presented at the 2024 ASCO Annual Meeting. Tune in and hear about this important trial from the lead author.

Podcast Host:

Narjust Florez, MD, Associate Director of the Cancer Care Equity Program and Thoracic Medical Oncologist, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, Boston, MA, USA

Podcast Guests:

Suresh Ramalingam, MD, FACP, FASCO, Executive Director, Winship Cancer Institute, Emory University, Atlanta, GA, USA